NCT02531854 2023-12-19
A Study of Pemetrexed Maintenance With or Without ADXS11-001 Immunotherapy in Patients With Human Papillomavirus Positive (HPV+), NSCLC Following First-Line Induction Chemotherapy
Advaxis, Inc.
Phase 2 Withdrawn
Advaxis, Inc.
Novartis
Agenus Inc.
Bristol-Myers Squibb
NextCure, Inc.
Hoffmann-La Roche
Incyte Corporation
Incyte Corporation